USD10
ZBIO Shares
About Zenas BioPharmaZenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
USD10
ZBIO Shares
About Zenas BioPharmaZenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 27 at 1:30 PM GMT+0
MARKET CAP
$966.76M
OPEN PRICE
$19.23
LOW (1Y)
$6.11
HIGH (1Y)
$44.60
LOW (24H)
$17.20
HIGH (24H)
$19.35
VOLUME (24H)
$3.36M
1,150.86%
Price history
Time | Price | Change |
|---|---|---|
Today | $19.23 | |
1 Day | $20.00 | |
1 Week | $21.77 | |
1 Month | $25.57 | |
1 Year | $8.17 |